Merck Stock Faces Scrutiny Over 110% Surge

Merck's stock price has surged by nearly 110% over the past five years, leaving investors to wonder whether its current value is justified. Recent approvals and trial results in oncology and other specialties may support expectations for new treatment-driven cash flows as the company works to offset future patent risks around Keytruda.

The issue now is whether Merck's current share price can be explained by the cash flows implied by its intrinsic value estimate. To pressure test this, it can help to compare it with other large pharmaceutical players and see how they measure on resilient stocks with low risk scores.

Using a Discounted Cash Flow (DCF) model, analysts project what Merck's future free cash generation could be worth in today's money. On the latest twelve month numbers, Merck produced about $16.1b of free cash flow, and the DCF framework assumes this cash base continues to grow rather than shrink over the coming decade.

Analysts and internal estimates feeding the model point to Merck's annual free cash flow rising into the mid 20b range by 2030, with growth then easing into a steadier phase. Because the DCF projections put Merck's estimated intrinsic value substantially above the current share price of $145.31, the market price implies a meaningful discount to this cash flow profile.